Shares of Nanobiotix S.A. – Sponsored ADR (NASDAQ:NBTX – Get Free Report) gapped down before the market opened on Tuesday. The stock had previously closed at $30.66, but opened at $27.90. Nanobiotix shares last traded at $27.36, with a volume of 7,020 shares.
Wall Street Analyst Weigh In
A number of research firms recently commented on NBTX. Guggenheim assumed coverage on shares of Nanobiotix in a report on Tuesday, September 15th. They issued a “buy” rating and a $64.00 price target on the stock. Weiss Ratings reissued a “sell (d-)” rating on shares of Nanobiotix in a report on Thursday, October 15th. Four research analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the stock. According to data from MarketBeat, the stock has an average rating of “Moderate Buy” and a consensus price target of $46.67.
Get Our Latest Report on Nanobiotix
Nanobiotix Stock Down 3.4%
The company’s fifty day moving average is $30.13 and its 200 day moving average is $34.24.
Hedge Funds Weigh In On Nanobiotix
A hedge fund recently bought a new stake in Nanobiotix stock. Aquatic Capital Management LLC acquired a new position in shares of Nanobiotix S.A. – Sponsored ADR (NASDAQ:NBTX – Free Report) during the third quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor acquired 2,118 shares of the company’s stock, valued at approximately $66,000. 38.81% of the stock is currently owned by institutional investors and hedge funds.
About Nanobiotix
Nanobiotix is a French biotechnology company developing nanoparticle-based treatments for cancer. Founded in 2003, the company focuses on using nanomedicine to enhance the effects of established cancer therapies, particularly radiation therapy. Its lead product candidate, NBTXR3, is made from hafnium oxide nanoparticles and is designed to be injected directly into a tumor. When exposed to radiation, the particles are intended to increase damage to cancer cells while limiting the effect on surrounding healthy tissue.
Read More
- Five stocks we like better than Nanobiotix
- Banking on AI: Can Upstart’s New Bank Plan Turn Its Stock Around?
- Amazon’s Black Friday Rush Could Kick Off a Holiday Season That Defines Its Year
- The Next Nuclear Opportunity May Be in Fuel, Not Reactors: 3 Stocks to Watch
- Tyson Foods’ Earnings Beat Hides a Warning for Consumer Staples Dividend Investors
Receive News & Ratings for Nanobiotix Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Nanobiotix and related companies with MarketBeat.com's FREE daily email newsletter.
